Tianshui Zhongxing Bio-technology Co Ltd (SHE:002772) — Stock Price
Tianshui Zhongxing Bio-technology Co Ltd (SHE:002772) is currently trading at CN¥10.64 CNY, down 2.83% today. Over the past 52 weeks, shares have ranged between CN¥9.30 and CN¥19.57. This page tracks Tianshui Zhongxing Bio-technology Co Ltd's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 002772 market cap overview.
Tianshui Zhongxing Bio-technology Co Ltd (002772) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Tianshui Zhongxing Bio-technology Co Ltd's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Tianshui Zhongxing Bio-technology Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Tianshui Zhongxing Bio-technology Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥2.10 Billion | CN¥1.94 Billion | CN¥1.93 Billion | CN¥1.97 Billion | CN¥1.56 Billion |
| Cost of Revenue | CN¥1.51 Billion | CN¥1.54 Billion | CN¥1.49 Billion | CN¥1.47 Billion | CN¥1.27 Billion |
| Gross Profit | CN¥586.29 Million | CN¥390.27 Million | CN¥436.86 Million | CN¥497.69 Million | CN¥287.97 Million |
| Research & Development | CN¥15.52 Million | CN¥15.51 Million | CN¥12.92 Million | CN¥10.41 Million | CN¥7.17 Million |
| SG&A | CN¥181.43 Million | CN¥84.63 Million | CN¥85.39 Million | CN¥82.29 Million | CN¥76.83 Million |
| Total Operating Expenses | CN¥257.87 Million | CN¥265.06 Million | CN¥277.94 Million | CN¥331.50 Million | CN¥204.61 Million |
| Operating Income | CN¥328.43 Million | CN¥125.21 Million | CN¥158.92 Million | CN¥166.19 Million | CN¥83.36 Million |
| EBITDA | CN¥583.75 Million | CN¥490.01 Million | CN¥511.87 Million | CN¥524.77 Million | CN¥392.66 Million |
| EBIT | CN¥328.43 Million | CN¥203.66 Million | CN¥243.16 Million | CN¥249.39 Million | CN¥135.18 Million |
| Interest Expense | CN¥56.99 Million | CN¥77.06 Million | CN¥83.61 Million | CN¥90.49 Million | CN¥80.87 Million |
| Income Before Tax | CN¥335.80 Million | CN¥126.60 Million | CN¥159.56 Million | CN¥158.90 Million | CN¥54.32 Million |
| Income Tax Expense | CN¥1.21 Million | — | CN¥3.26 Million | CN¥4.05K | CN¥66.67 Million |
| Net Income | CN¥334.96 Million | CN¥128.03 Million | CN¥159.58 Million | CN¥158.35 Million | CN¥54.97 Million |
Tianshui Zhongxing Bio-technology Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Tianshui Zhongxing Bio-technology Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥7.09 Billion | CN¥6.19 Billion | CN¥6.07 Billion | CN¥6.57 Billion | CN¥6.55 Billion |
| Total Current Assets | CN¥3.40 Billion | CN¥2.83 Billion | CN¥2.66 Billion | CN¥3.04 Billion | CN¥3.08 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥353.06 Million | CN¥325.48 Million | CN¥285.00 Million | CN¥369.51 Million | CN¥263.43 Million |
| Net Receivables | CN¥50.09 Million | CN¥38.62 Million | CN¥28.29 Million | CN¥37.95 Million | CN¥21.60 Million |
| Inventory | CN¥1.52 Billion | CN¥1.25 Billion | CN¥1.27 Billion | CN¥1.26 Billion | CN¥1.17 Billion |
| Property, Plant & Equipment | — | — | — | CN¥3.07 Billion | CN¥3.01 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥3.43 Billion | CN¥2.87 Billion | CN¥2.64 Billion | CN¥3.18 Billion | CN¥3.30 Billion |
| Total Current Liabilities | CN¥1.43 Billion | CN¥1.71 Billion | CN¥1.46 Billion | CN¥1.44 Billion | CN¥819.53 Million |
| Long-term Debt | CN¥1.88 Billion | CN¥1.06 Billion | CN¥1.07 Billion | CN¥1.62 Billion | CN¥2.33 Billion |
| Net Debt | CN¥1.44 Billion | CN¥483.89 Million | CN¥346.53 Million | CN¥1.28 Billion | CN¥1.16 Billion |
| Total Stockholder Equity | CN¥3.53 Billion | CN¥3.32 Billion | CN¥3.43 Billion | CN¥3.38 Billion | CN¥3.25 Billion |
| Retained Earnings | CN¥1.16 Billion | CN¥957.83 Million | CN¥958.93 Million | CN¥931.46 Million | CN¥819.41 Million |
Tianshui Zhongxing Bio-technology Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Tianshui Zhongxing Bio-technology Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥503.52 Million | CN¥494.52 Million | CN¥524.50 Million | CN¥493.70 Million | CN¥-413.68 Million |
| Capital Expenditures | CN¥551.55 Million | CN¥245.15 Million | CN¥107.00 Million | CN¥245.86 Million | CN¥286.47 Million |
| Free Cash Flow | CN¥-48.04 Million | CN¥249.36 Million | CN¥395.48 Million | CN¥247.84 Million | CN¥-700.15 Million |
| Investing Cash Flow | CN¥-568.12 Million | CN¥-284.07 Million | CN¥-56.96 Million | CN¥-380.39 Million | CN¥164.09 Million |
| Financing Cash Flow | CN¥259.58 Million | CN¥-59.76 Million | CN¥-755.20 Million | CN¥-367.93 Million | CN¥630.14 Million |
| Dividends Paid | CN¥112.42 Million | CN¥199.56 Million | CN¥210.79 Million | CN¥39.29 Million | CN¥34.80 Million |
| Stock-Based Compensation | — | — | — | CN¥10.85 Million | CN¥28.04 Million |
| Depreciation | CN¥255.32 Million | CN¥286.54 Million | CN¥268.72 Million | CN¥275.40 Million | CN¥257.49 Million |
| Change in Cash | CN¥258.60 Million | CN¥150.68 Million | CN¥-287.66 Million | CN¥-254.62 Million | CN¥380.55 Million |
Tianshui Zhongxing Bio-technology Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Tianshui Zhongxing Bio-technology Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 30, 2026 | 0.07 | — | — |
| Mar 31, 2026 | 0.43 | — | — |
| Dec 31, 2025 | 0.35 | — | — |
| Sep 30, 2025 | 0.36 | — | — |
| Jun 30, 2025 | 0.06 | — | — |
| Apr 16, 2025 | 0.13 | — | — |
| Dec 31, 2024 | 0.10 | — | — |
| Sep 30, 2024 | 0.15 | — | — |